3D printed lattices as an activation and expansion platform for T cell therapy

Bahman Delalat, Frances Harding, Batjargal Gundsambuu, Elena M. De-Juan-Pardo, Felix M. Wunner, Marie Luise Wille, Marek Jasieniak, Kristen A.L. Malatesta, Hans J. Griesser, Antonio Simula, Dietmar W. Hutmacher, Nicolas H. Voelcker, Simon C. Barry

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

One of the most significant hurdles to the affordable, accessible delivery of cell therapy is the cost and difficulty of expanding cells to clinically relevant numbers. Immunotherapy to prevent autoimmune disease, tolerate organ transplants or target cancer critically relies on the expansion of specialized T cell populations. We have designed 3D-printed cell culture lattices with highly organized micron-scale architectures, functionalized via plasma polymerization to bind monoclonal antibodies that trigger cell proliferation. This 3D technology platform facilitate the expansion of therapeutic human T cell subsets, including regulatory, effector, and cytotoxic T cells while maintaining the correct phenotype. Lentiviral gene delivery to T cells is enhanced in the presence of the lattices. Incorporation of the lattice format into existing cell culture vessels such as the G-Rex system is feasible. This cell expansion platform is user-friendly and expedites cell recovery and scale-up, making it ideal for translating T cell therapies from bench to bedside.

Original languageEnglish
Pages (from-to)58-68
Number of pages11
JournalBiomaterials
Volume140
DOIs
Publication statusPublished - 1 Sep 2017
Externally publishedYes

Fingerprint

T-cells
Cell- and Tissue-Based Therapy
Chemical activation
T-Lymphocytes
Cell culture
Cell Culture Techniques
T-Lymphocyte Subsets
Plasma polymerization
Transplants
Monoclonal antibodies
Polymerization
Immunotherapy
Autoimmune Diseases
Cell proliferation
Monoclonal Antibodies
Cell Proliferation
Technology
Phenotype
Costs and Cost Analysis
Genes

Cite this

Delalat, B., Harding, F., Gundsambuu, B., De-Juan-Pardo, E. M., Wunner, F. M., Wille, M. L., ... Barry, S. C. (2017). 3D printed lattices as an activation and expansion platform for T cell therapy. Biomaterials, 140, 58-68. https://doi.org/10.1016/j.biomaterials.2017.05.009
Delalat, Bahman ; Harding, Frances ; Gundsambuu, Batjargal ; De-Juan-Pardo, Elena M. ; Wunner, Felix M. ; Wille, Marie Luise ; Jasieniak, Marek ; Malatesta, Kristen A.L. ; Griesser, Hans J. ; Simula, Antonio ; Hutmacher, Dietmar W. ; Voelcker, Nicolas H. ; Barry, Simon C. / 3D printed lattices as an activation and expansion platform for T cell therapy. In: Biomaterials. 2017 ; Vol. 140. pp. 58-68.
@article{8f6c1d9f994e4d8b8c2b55d735da676d,
title = "3D printed lattices as an activation and expansion platform for T cell therapy",
abstract = "One of the most significant hurdles to the affordable, accessible delivery of cell therapy is the cost and difficulty of expanding cells to clinically relevant numbers. Immunotherapy to prevent autoimmune disease, tolerate organ transplants or target cancer critically relies on the expansion of specialized T cell populations. We have designed 3D-printed cell culture lattices with highly organized micron-scale architectures, functionalized via plasma polymerization to bind monoclonal antibodies that trigger cell proliferation. This 3D technology platform facilitate the expansion of therapeutic human T cell subsets, including regulatory, effector, and cytotoxic T cells while maintaining the correct phenotype. Lentiviral gene delivery to T cells is enhanced in the presence of the lattices. Incorporation of the lattice format into existing cell culture vessels such as the G-Rex system is feasible. This cell expansion platform is user-friendly and expedites cell recovery and scale-up, making it ideal for translating T cell therapies from bench to bedside.",
keywords = "3D lattice, Cell therapy manufacturing, Immunotherapy, Melt electrospin writing, Plasma polymer functionalization",
author = "Bahman Delalat and Frances Harding and Batjargal Gundsambuu and De-Juan-Pardo, {Elena M.} and Wunner, {Felix M.} and Wille, {Marie Luise} and Marek Jasieniak and Malatesta, {Kristen A.L.} and Griesser, {Hans J.} and Antonio Simula and Hutmacher, {Dietmar W.} and Voelcker, {Nicolas H.} and Barry, {Simon C.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.biomaterials.2017.05.009",
language = "English",
volume = "140",
pages = "58--68",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier",

}

Delalat, B, Harding, F, Gundsambuu, B, De-Juan-Pardo, EM, Wunner, FM, Wille, ML, Jasieniak, M, Malatesta, KAL, Griesser, HJ, Simula, A, Hutmacher, DW, Voelcker, NH & Barry, SC 2017, '3D printed lattices as an activation and expansion platform for T cell therapy' Biomaterials, vol. 140, pp. 58-68. https://doi.org/10.1016/j.biomaterials.2017.05.009

3D printed lattices as an activation and expansion platform for T cell therapy. / Delalat, Bahman; Harding, Frances; Gundsambuu, Batjargal; De-Juan-Pardo, Elena M.; Wunner, Felix M.; Wille, Marie Luise; Jasieniak, Marek; Malatesta, Kristen A.L.; Griesser, Hans J.; Simula, Antonio; Hutmacher, Dietmar W.; Voelcker, Nicolas H.; Barry, Simon C.

In: Biomaterials, Vol. 140, 01.09.2017, p. 58-68.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 3D printed lattices as an activation and expansion platform for T cell therapy

AU - Delalat, Bahman

AU - Harding, Frances

AU - Gundsambuu, Batjargal

AU - De-Juan-Pardo, Elena M.

AU - Wunner, Felix M.

AU - Wille, Marie Luise

AU - Jasieniak, Marek

AU - Malatesta, Kristen A.L.

AU - Griesser, Hans J.

AU - Simula, Antonio

AU - Hutmacher, Dietmar W.

AU - Voelcker, Nicolas H.

AU - Barry, Simon C.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - One of the most significant hurdles to the affordable, accessible delivery of cell therapy is the cost and difficulty of expanding cells to clinically relevant numbers. Immunotherapy to prevent autoimmune disease, tolerate organ transplants or target cancer critically relies on the expansion of specialized T cell populations. We have designed 3D-printed cell culture lattices with highly organized micron-scale architectures, functionalized via plasma polymerization to bind monoclonal antibodies that trigger cell proliferation. This 3D technology platform facilitate the expansion of therapeutic human T cell subsets, including regulatory, effector, and cytotoxic T cells while maintaining the correct phenotype. Lentiviral gene delivery to T cells is enhanced in the presence of the lattices. Incorporation of the lattice format into existing cell culture vessels such as the G-Rex system is feasible. This cell expansion platform is user-friendly and expedites cell recovery and scale-up, making it ideal for translating T cell therapies from bench to bedside.

AB - One of the most significant hurdles to the affordable, accessible delivery of cell therapy is the cost and difficulty of expanding cells to clinically relevant numbers. Immunotherapy to prevent autoimmune disease, tolerate organ transplants or target cancer critically relies on the expansion of specialized T cell populations. We have designed 3D-printed cell culture lattices with highly organized micron-scale architectures, functionalized via plasma polymerization to bind monoclonal antibodies that trigger cell proliferation. This 3D technology platform facilitate the expansion of therapeutic human T cell subsets, including regulatory, effector, and cytotoxic T cells while maintaining the correct phenotype. Lentiviral gene delivery to T cells is enhanced in the presence of the lattices. Incorporation of the lattice format into existing cell culture vessels such as the G-Rex system is feasible. This cell expansion platform is user-friendly and expedites cell recovery and scale-up, making it ideal for translating T cell therapies from bench to bedside.

KW - 3D lattice

KW - Cell therapy manufacturing

KW - Immunotherapy

KW - Melt electrospin writing

KW - Plasma polymer functionalization

UR - http://www.scopus.com/inward/record.url?scp=85020496887&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2017.05.009

DO - 10.1016/j.biomaterials.2017.05.009

M3 - Article

VL - 140

SP - 58

EP - 68

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -